{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:00:34Z","timestamp":1789182034430,"version":"build-2803163510"},"reference-count":67,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Entry inhibitors are a relatively new class of antiretroviral therapy and are typically indicated in heavily treatment experienced individuals living with HIV. Despite this, there is no formal definition of \u2018heavily treatment experienced\u2019. Interpretation of this term generally includes acknowledgement of multidrug resistance and reflects the fact that patients in need of further treatment options may have experienced multiple lines of therapy. However, it fails to recognize treatment limiting factors including contraindications, age\u2010associated comorbidities, and difficulty adhering to regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This manuscript follows a roundtable discussion and aims to identify the unmet needs of those living with HIV who are in need of further treatment options, to broaden the definition of heavily treatment experienced and to clarify the use of newer agents, with an emphasis on the potential role of entry inhibitors, in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results\/Conclusions<\/jats:title><jats:p>Within the entry inhibitor class, mechanisms of action differ between agents; resistance to one subclass does not confer resistance to others. Combinations of entry inhibitors should be considered in the same regimen, and if lack of response is seen to one entry inhibitor another can be tried. When selecting an entry inhibitor, physicians should account for patient preferences and needs as well as agent\u2010specific clinical characteristics. Absence of documented multidrug resistance should not exclude an individual from treatment with an entry inhibitor; entry inhibitors are a valuable treatment option for all individuals who are treatment limited or treatment exhausted. We should advocate for additional clinical trials that help define the role of entry inhibitors in people with exhausted\/limited ART options other than drug resistance.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13288","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T07:48:06Z","timestamp":1647416886000},"page":"936-946","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment\u2010limited individuals living with HIV"],"prefix":"10.1111","volume":"23","author":[{"given":"Chloe","family":"Orkin","sequence":"first","affiliation":[{"name":"Queen Mary University London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cahn","sequence":"additional","affiliation":[{"name":"Fundacion Huesped  Buenos Aires Argentina"},{"name":"Buenos Aires University Medical School  Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Vita\u2010Salute San Raffaele University San Raffaele Scientific Institute  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brinda","family":"Emu","sequence":"additional","affiliation":[{"name":"Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00a0Richard","family":"Harrigan","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver BC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schapiro","sequence":"additional","affiliation":[{"name":"Sheba Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"World Health Organization.HIV\/AIDS.2021.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hiv\u2010aids. Accessed January 7 2022."},{"key":"e_1_2_9_3_1","first-page":"1987","article-title":"Investigational drugs in HIV: pros and cons of entry and fusion inhibitors","volume":"19","author":"Venanzi Rullo E","year":"2019","journal-title":"Mol Med Rep"},{"key":"e_1_2_9_4_1","unstructured":"EACS Guidelines version 11.0 October 2021.https:\/\/www.eacsociety.org\/guidelines\/eacs\u2010guidelines\/. Accessed January 7 2022."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab562"},{"key":"e_1_2_9_6_1","unstructured":"Pelchen\u2010MatthewsA BorgesAH ReekieJ et al.Prevalence and outcomes for heavily treatment\u2010experienced (HTE) individuals living with HIV in a European cohort. 10th IAS Conference on HIV Science (IAS 2019) July 21\u201024 2019 Mexico City. Abstract TUPEB222."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002679"},{"key":"e_1_2_9_8_1","unstructured":"European Medicines Agency.Rukobia (fostemsavir).2021.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rukobia. Accessed January 7 2022."},{"key":"e_1_2_9_9_1","unstructured":"European Medicines Agency.Trogarzo (ibalizumab).2021.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trogarzo. Accessed January 7 2022."},{"key":"e_1_2_9_10_1","unstructured":"ClinicalInfoHIV.gov.Drug database: albuvirtide.2020.https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/albuvirtide\/patient. Accessed January 7 2022."},{"key":"e_1_2_9_11_1","unstructured":"European Medicines Agency.Celsentri (maraviroc).2020.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/celsentri. Accessed January 7 2022."},{"key":"e_1_2_9_12_1","unstructured":"European Medicines Agency.Fuzeon (enfuvirtide).2021.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fuzeon. Accessed January 7 2022."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803152"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035026"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006866"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328324bbec"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307953101"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2010.09.017"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.8.4784-4793.1992"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.107.042101"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.12.1837"},{"key":"e_1_2_9_24_1","first-page":"313","article-title":"[Enfuvirtide, mechanism of action and pharmacological properties]","volume":"59","author":"Kapi\u0107 E","year":"2005","journal-title":"Med Arh"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.2.986-993.1998"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.8.4991-4999.2005"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02413-06"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.6.2790-2807.2004"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01863-12"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp482"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00374-10"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01109-10"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204099"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00761-05"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4721-4732.2005"},{"key":"e_1_2_9_38_1","unstructured":"ClinicalTrials.gov.Albuvirtide in combination with 3BNC117 in patients with multi\u2010drug resistant (MDR) HIV\u20101 infection.2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04560569. Accessed January 7 2022."},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L265"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct0902-83"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-014-0040-9"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1310\/1W4A-R6MN-99Q4-1GNM"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12129"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225381"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109712462454"},{"key":"e_1_2_9_46_1","unstructured":"FDA.SELEZENTRY (maraviroc) prescribing information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022128Orig1s019 208984Orig1s002lbl.pdf. Accessed January 7 2022."},{"key":"e_1_2_9_47_1","first-page":"872396","article-title":"Clinic attendance for medication refills and medication adherence amongst an antiretroviral treatment cohort in Uganda: a prospective study","volume":"2010","author":"Kunutsor S","year":"2010","journal-title":"AIDS Res Treat"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00992-6"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2013.s1.e5"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.014"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120410001683402"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120050042891"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.8.764"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1300\/J013v36n01_07"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200101010-00012"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/843794"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-017-4309-5"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120802511968"},{"key":"e_1_2_9_59_1","first-page":"419","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta\u2010analysis","volume":"7","author":"Srivastava K","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S31385"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30179-6"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1670"},{"key":"e_1_2_9_63_1","unstructured":"FDA.RUKOBIA (fostemsavir) prescribing information.2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212950s000lbl.pdf. Accessed January 7 2022."},{"key":"e_1_2_9_64_1","unstructured":"FDA.TROGARZO (ibalizumab) prescribing information.2021.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761065s011lbl.pdf. Accessed January 7 2022."},{"key":"e_1_2_9_65_1","unstructured":"FDA.FUZEON (enfuvirtide) for injection.2019.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021481s033lbl.pdf. Accessed January 7 2022."},{"key":"e_1_2_9_66_1","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.2021.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed January 7 2022."},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035211"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn377"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13288","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13288","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:51:35Z","timestamp":1692751895000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/hiv.13288"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13288","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"2021-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}